News & Events about Design Therapeautics Inc.
Design Therapeutics (NASDAQ:DSGN Get Rating) and Cadrenal Therapeutics (NASDAQ:CVKD Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, ...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc. - DSGN SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc. - DSGN PR Newswire NEW YORK, Jan. 4, 2023 NEW YORK, Jan. 4, 2023...
NEW YORK, Dec. 30, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Design Therapeutics, Inc. (Design or the Company) (NASDAQ: DSGN) on behalf of Design stockholders. Our investigation concerns ...
NEW YORK, Dec. 24, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Design Therapeutics, Inc. (Design or the Company) (NASDAQ:DSGN). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The ...
Design Therapeutics, Inc. (NASDAQ:DSGN Get Rating) Director Simeon George purchased 360,000 shares of the stock in a transaction dated Monday, December 19th. The stock was acquired at an average cost of $8.63 per share, for a total transaction of $3,106,800.00. Following the completion of ...